In Segment C, individuals will obtain ABBV-744 and oral navitoclax. In Section D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or maybe the members are not able to tolerate the study drugs. 88 These preclinical studies offer paradigms for potential clinical trials in https://abbv-744andotherbrd4inhib80134.nizarblog.com/32196468/abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers-secrets